在治疗儿科B细胞白血病方面,新的CAR-T细胞疗法的响应率超过99%。 New CAR-T cell therapy shows over 99% response rate in treating pediatric B-cell leukemia.

为患有复发性或难于治疗的B细胞急性淋巴性白血病(B-ALL)的儿童进行的新的CAR-T细胞疗法已显示出可喜的成果。 A new CAR-T cell therapy for children with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (B-ALL) has shown promising results. 该研究涉及343名儿科病人,报告答复率为99.1%,其中75.5%在一年内未重发疾病而幸存,总存活率为93.5%。 The study, involving 343 pediatric patients, reported a 99.1% response rate, with 75.5% surviving without disease recurrence and 93.5% overall survival at one year. 虽然所有病人都患有细胞素释放综合症(CRS),这是常见的副作用,但其严重程度与疾病负担而不是治疗剂量有关。 While all patients experienced cytokine release syndrome (CRS), a common side effect, the severity was linked to disease burden rather than the therapy dose. 第一阶段试验目前正在进一步测试治疗方法。 A phase I trial is now testing the therapy further.